The insight for us to test the effect of exogenous IL‐6 treatment on MBD2_v2 expression, and subsequently observe that upregulated MBD2_v2 increases PCa CSCs, is based on results of our investigation into how ROS signaling promotes malignant transformation and the stem cell phenotype in triple negative breast cancer cells (Bao et al., 2017). Here, IL6 is linked to triple-negative breast carcinoma.